摘要
目的 探讨乳腺非特殊型浸润性导管癌中MGMT和XRCC1的表达及临床意义.方法 采用S-P免疫组化法检测72例乳腺非特殊型浸润性导管癌石蜡标本、30例乳腺良性病变石蜡标本中MGMT和XRCC1蛋白的表达,分析其表达与临床因素的相关性.结果 72例乳腺癌组织中MGMT阳性表达率为70.8%,低于良性病变组织表达率90.0%（P＜0.05）,且其表达与非特殊型浸润性导管癌的病理分化程度、ER及p53表达相关（P＜0.05）.XRCC1阳性表达率为52.8%,低于良性病变组织表达率83.3%（P＜0.05）,且其表达与非特殊型浸润性导管癌病理分化程度相关（P＜0.05）.结论 DNA修复基因MGMT及XRCC1是临床评估乳腺癌恶性程度、判断预后及制定治疗策略的重要病理指标.
Objective To investigate the expression of MGMT and XRCC1 in invasive ductal carcinoma （ IDC）, and to explore the relationship between clinical factors. Methods Immunohistochemistry （ S - P） was performed for MGMT and XRCC1 on 72 specimens of IDC ,30 specimens of benign breast lesions. Results The positive expression rate of MGMT in IDC was 70.8% ,lower than which expression in benign breast lesions, which had correlation with pathological grades of invasive duetal carcinoma（IDC） and the expression of ER and p53 （P 〈0.05）. The positive expression rate of XRCC1 was 52.8% ,lower than which expression in benign breast le- sions,which had correlation with the pathological grades of IDC. Conclusion They were important pathological signs to evaluate the malignancy degree and prognosis of the breast cancer. These markers play an important role in making sure the treatment prescription for breast cancer patients.
出处
《实用肿瘤学杂志》
CAS
2010年第2期130-133,137,共5页
Practical Oncology Journal
基金
黑龙江省科技攻关项目（编号：GB08C401-01）
